GW Pharmaceuticals PLC (GWPH) Getting Somewhat Positive Press Coverage, Study Finds
Media headlines about GW Pharmaceuticals PLC (NASDAQ:GWPH) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC earned a news impact score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.4073968339844 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- GW Pharmaceuticals PLC (GWPH), Altisource Portfolio Solutions SA (ASPS) Shares Moving On Volume – Evergreen Caller (evergreencaller.com)
- Are Discerning Investors Interested in These Shares: GW Pharmaceuticals plc (NASDAQ:GWPH)? – FLBC News (flbcnews.com)
- Primed for Breakout or Bust? A look at GW Pharmaceuticals plc (NASDAQ:GWPH) and Ingevity Corporation (NYSE … – FLBC News (flbcnews.com)
- What You Need to Know About the 3 Kinds of Marijuana Stocks (finance.yahoo.com)
- Stocks in the Limelight: GW Pharmaceuticals plc (NASDAQ:GWPH), RBC Bearings Incorporated (NASDAQ:ROLL) – FLBC News (flbcnews.com)
Several analysts have recently weighed in on GWPH shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $208.00 price objective on shares of GW Pharmaceuticals PLC in a report on Tuesday, May 9th. Maxim Group reaffirmed a “buy” rating and set a $135.00 price objective on shares of GW Pharmaceuticals PLC in a report on Thursday, May 25th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Monday, May 15th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus target price of $148.55.
Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at 104.97 on Wednesday. GW Pharmaceuticals PLC has a 1-year low of $79.71 and a 1-year high of $137.88. The company’s market capitalization is $2.66 billion. The stock’s 50 day moving average is $107.46 and its 200 day moving average is $112.28.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing the consensus estimate of ($1.73) by $0.34. The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same period last year, the business posted ($0.05) earnings per share. On average, equities research analysts anticipate that GW Pharmaceuticals PLC will post ($6.10) EPS for the current fiscal year.
WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/30/gw-pharmaceuticals-plc-gwph-getting-somewhat-positive-press-coverage-study-finds.html.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.